1-3 of 3
Maribeth Hohenstein
Close
Sort by
Journal Articles

A Single-Center Phase IIa Study Evaluating the Safety and Tolerability of Umbralisib and Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Matthew A. Lunning, DO, Philip Bierman, MD, R. Gregory Bociek, MD, James O. Armitage, MD, Peggy Heires, R.N., Maribeth Hohenstein, R.N, Susan Blumel, RN, Jonathan Tefft, B.A., Elizabeth R. Lyden, MS, Michael R Green, PhD, Julie M. Vose, MD MBA
Journal: Blood
Blood (2018) 132 (Supplement 1): 5390.
https://doi.org/10.1182/blood-2018-99-119765
Published: 2018
Journal Articles

Phase I/II Study of Dasatinib In Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)

Basem M. William, MD, MRCP, Maribeth Hohenstein, RN, BSN, OCN, Fausto R. Loberiza, Jr., MD, MS, Gabriel C. Caponetti, MD, R. Gregory Bociek, MD, Philip Bierman, MD, James O. Armitage, MD, Wing-Chung Chan, MD, Julie M. Vose, MD
Journal: Blood
Blood (2010) 116 (21): 288.
https://doi.org/10.1182/blood.V116.21.288.288
Published: 2010
Journal Articles

A Phase 1/2A Open-Label Study of Pralatrexate and Gemcitabine in Patients with Relapsed or Refractory Lymphoproliferative Malignancies.

Steven M. Horwitz, MD, Julie M. Vose, MD, Ranjana Advani, MD, Kamalesh Sankhala, MD, Swaminathan Padmanabhan, M.D., Paul A. Hamlin, Jr., MD, Andy Chen, MD, PhD, Shannon Wilroy, Jasmine M. Zain, MD, Danielle Wright, Hanna Weissbrot, Maribeth Hohenstein, Pablo J Cagnoni, MD, Michael E Saunders, MD, Owen A. O’Connor, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 1570.
https://doi.org/10.1182/blood.V112.11.1570.1570
Published: 2008